Corellia is a Champions Oncology spin-out leveraging the world’s largest living PDX tumor bank and AI-enabled discovery to develop first-in-class ADC and radioligand therapies for hard-to-treat and resistance-driven cancers. Our lead CD180 program for hematologic malignancies shows strong in-vivo efficacy, clean cyno safety, and high manufacturability, alongside a CDH17-targeted radioligand program. We are also advancing a differentiated linker-payload platform with broad applicability. We are currently seeking strategic collaborations and investment partnerships.